TABLE 3.
Maximum sensitivity performance of all remaining subset models after an assay exclusion.
| Assay ID | Absence of assay endpoint | Max sensitivity | |
|---|---|---|---|
| Antagonist | Agonist | ||
| A1, A2, and A3 | All receptor-binding assays (antagonist and agonist pathway) | 95.6 | 89.3 |
| A1 | Receptor-binding assay NVS_NR_hAR (antagonist and agonist pathway) | 97.2 | 96.4 |
| A2 | Receptor-binding assay NVS_NR_cAR (antagonist and agonist pathway) | 97.2 | 100 |
| A3 | Receptor-binding assay NVS_NR_rAR (antagonist and agonist pathway) | 98 | 96.4 |
| A4 | Coregulator recruitment assay OT_AR_ARSRC1_0480 (antagonist and agonist pathway) | 97.6 | 100 |
| A5 | Coregulator recruitment assay OT_AR_ARSRC1_0960 (antagonist and agonist pathway) | 97.2 | 96.4 |
| A6 | Nuclear translocation assay UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist (antagonist and agonist pathway) | 98 | 100 |
| A7 | RNA reporter gene assays (ATG_AR_TRANS_up) (agonist pathway) | 100 | 96.4 |
| A8 | Reporter gene assay OT_AR_ARELUC_AG_1440 (agonist pathway) | 100 | 96.4 |
| A9 | Reporter gene assay TOX21_AR_BLA_Agonist_ratio (agonist pathway) | 100 | 89.3 |
| A10 | Reporter gene assay TOX21_AR_LUC_MDAKB2_Agonist (agonist pathway) | 100 | 96.4 |
| A11 | Real-time impedance assay (ACEA_AR_agonist_80h) (agonist pathway) | 100 | 89.3 |
| A12 | Nuclear translocation assay UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist (antagonist pathway) | 83.6 | 100 |
| A13 | Reporter gene assay TOX21_AR_BLA_Antagonist_ratio (antagonist pathway) | 93.2 | 100 |
| A14 | Reporter gene assay TOX21_AR_LUC_MDAKB2_Antagonist_0.5 nM_R1881 (antagonist pathway) | 92 | 100 |
The “Max sensitivity” columns consider all remaining subset models.